Single-dose parvo treatment gets USDA approvalMay 3, 2023Elanco’s Canine Parvovirus Monoclonal Antibody treatment may provide a less intensive solution by targeting the virus with single-dose efficacy in dogs.
SPONSORED CONTENTFeline urinary health—meet a simple solutionUrinary health is complicated, but the solution doesn’t have to be. Our products nutritionally support urinary tract and bladder health at any stage. + Recommend Today
Feline diabetes pill gets FDA green lightDecember 9, 2022Bexacat has been approval by the U.S. Food and Drug Administration (FDA) for improved glycemic control in diabetic cats. Developed by Elanco Animal Health, the oral medication, which contains the active ingredient bexagliflozin, marks the first sodium-glucose cotransporter 2 (SGLT2) inhibitor (i.e. not insulin) approved by FDA in any animal species, the agency reports.
Elanco closes $444M purchase of biopharma co.August 31, 2021Elanco Animal Health has expanded its reach into the veterinary dermatology market with the $444-million acquisition of biopharma company, Kindred Biosciences.
Canine lymphoma drug gets full approvalJuly 20, 2021Elanco’s Tanovea product contains the active ingredient rabacfosadine, an acyclic nucleotide phosphonate that kills rapidly growing tumor cells.
Elanco acquires biopharma co. in $440M dealJune 16, 2021A major player in the global animal health industry has expanded its reach into the veterinary dermatology market with the purchase of a biopharmaceutical company.
Oral flea, tick product for cats launchedMay 4, 2021Veterinarians in the U.S. now have an orally administered option for controlling fleas and ticks in feline patients.
National study to shed light on canine OAMarch 22, 2021Gaining insight into the incidence and prevalence of canine osteoarthritis (OA) is the driving force behind a newly announced partnership.
Indiana to welcome animal co.’s global HQDecember 29, 2020Elanco Animal Health, Inc., has selected a downtown Indianapolis location for its new global headquarters.
Parvo preventative picks up speedDecember 29, 2020Elanco Animal Health is set to acquire the global rights to Kindred Biosciences’ proprietary KIND-030, a monoclonal antibody being developed for the treatment and prevention of canine parvovirus.
Pets, people, and planet inspire “healthy purpose” goalsOctober 28, 2020Improving human access to food resources, reducing environmental impact, and supporting the welfare of pets are the driving forces behind Elanco Animal Health’s new “healthy purpose” initiatives.
